REQUEST FOR INFORMATION

1.0 RFI TITLE: IN VITRO Absorption, distribution, metabolism, and excretion (ADME) CHEMICAL SCREENING support services

2.0 AGENCY: U.S. Army Medical Reserarch Acquisition Activity (USAMRAA)

3.0 OFFICE: U.S. Army Medical Research Institute of Chemical Defense (USAMRICD).

4.0 LOCATION: Ft. Detrick, MD

5.0 SUBJECT: USAMRICD is conducting market research to determine whether a commercial solution can be provided to meet requirements for the Chemical Screening Support Services.  This market research may also assist with the further development and/or refinement of the requirements.

6.0 DISCLAIMER: This is an RFI as defined in FAR 15.201(e) to ascertain whether a commercial item exists, which provides the capabilities described herein. This is an RFI as defined in FAR 15.201(e) to ascertain whether a commercial item exists, which provides the capabilities described herein.  

This RFI is issued solely for information and planning purposes and does not constitute a solicitation. Neither unsolicited proposals nor any other kind of offers will be considered in response to this RFI. Responses to this notice are not offers and will not be accepted by the Government to form a binding contract. In keeping with the standards of FAR Part 10, the Government may request additional information from responders. Responders are solely responsible for all expenses associated with responding to this RFI or any follow-up information request. All information received in response to this RFI or any follow-up information request that is marked Proprietary will be handled accordingly. Responses to the RFI will not be returned. At this time, questions concerning the composition and requirements for a future request for proposal will not be entertained.

7.0 DESCRIPTION: USAMRICD has a requirement for the following:

 In Vitro ADME Profiling on Five compounds provided by USAMRICD

Assays to Be Performed:

1) Aqueous Solubility at pH 7.4 (2% DMSO/PBS)

2) Stability in Physiological Fluids: Plasma, Simulated Gastric Fluid, Simulated Intestinal Fluid (One Concentration)

3) Stability in Liver Microsomes: 2 species, one concentration

4) Stability in Primary Human Hepatocytes, One Concentration

5) Inhibition of hERG in HEK293 Cells (Thalos® Ion Flux)

6) Plasma Protein Binding (Equilibrium Dialysis)

7) Parallel Artificial Membrane Permeation Assay

8) Blood Brain Barrier Parallel Artificial Membrane Permeation Assay

Results and Final Report:

Results of Assays 2, 3, and 4 will be reported as T1/2.

Results of 5 will be reported as IC50 or %inhibition at 10 uM. Results of 6 will be reported as % free, unbound.

Results of 7 and 8 will be reported as Papp (10-6 cm/sec) Results will be summarized in a report at the end of the study.

8.0 SUBMISSION INSTRUCTIONS: Responses from all capable and qualified sources are encouraged to respond to this request. 

White papers should adhere to the following formatting and outline instructions:

1.   All submissions shall be made electronically and be in one of the following formats: Microsoft Word or Adobe PDF.

a. Cover Page

i.              Title

ii.             Organization

iii.            Responder’s technical and administrative points of contact (names, addresses, phone numbers, and email addresses)

iv.            Description item(s) addressed above in section 7.0

b. Current Technical Expertise, Knowledge and Management Capability

i.              Executive Summary (i.e. synopsis of the responders capability to perform the tasks described herein)

ii.             Discussion of capabilities/challenges/technologies

iii.            Technical response, the breadth of disciplines and experience, relevance of Responder’s expertise that demonstrates a full understanding and experience in providing a commercial system available to meet the requirements for the Chemical Screening Services.

iv.            Rough order of magnitude (ROM) estimate of the cost to perform the scope of work

c. Brief summary of relevant experience pertaining to the requirement (for example government, academia or industry experience).   

Please note that responses are due no later than close of business on 16 August 2021. The only accepted method of submission is via email.  No evaluation letters and/or results will be issued to the respondents.  At this time no solicitation exists; therefore, please do not request a copy of the solicitation.  NO PHONE CALLS PLEASE.  It is the responsibility of any potential offeror to monitor this site for the release of any solicitation or synopsis.

9.0 SUBMISSION CONTACT INFORMATION:  Interested entities shall forward submissions to Ms. Renee Gardner at [email protected] no later than the close of business on 16 August 2021. Telephonic communication will not be considered as submission nor receive response.

10.0 REQUIRED INFORMATION:

RFI Number

Company Name

Company Address

Point of Contact

Phone Number

E-mail Address

Tax Identification Number (TIN)

CAGE Code

DUNS Number

Company Web Page

Company Location(s)

Confirm company is a Small Business

Company is / is not SAM Registered

Other Socio-Economic Classifications (e.g. 8(a), HUB Zone, Woman-Owned, Veteran-Owned, Service- Disabled Veteran-Owned)

If 8(a), date that the company graduates from the program